Aliases from NCBI:

Cellular immune response

In addition to humoral responses, NY-ESO-1 has been shown to elicit spontaneous cellular immune responses in patients with advanced stage tumors. In most cases, antibody and T cells responses occur simultaneously and in an integrated manner.

Integrated cellular and humoral immune responses against NY-ESO-1 have been detected in patients with:

- Hepatocellular carcinoma Korangy et al., 2004; Shang et al., 2004;

- Multiple myeloma Van Rhee et al., 2005;

- Sarcoma Ayyoub et al., 2004;

- Prostate carcinoma Nakada et al., 2003;

- Esophageal carcinoma Fugita et al., 2004.

Nakamura et al., 2009 (PMID: 19193472) observed strong CD4 and CD8 T-cell responses, specific to NY-ESO-1 in a patient with NSCLC that spontaneously regressed, possibly mediated by anti-NY-ESO-1 immunity.

NY-ESO-1-specific CD8+ T cells in TILs or TALs of ovarian cancer patients, were detected by direct ex vivo tetramer analysis (Matsuzaki et al., 2010 PMID: 20385810).

NY-ESO-1-specific CD8+ T cell responses spontaneously develop in a subset of patients harboring NY-ESO-1 expressing ATLL.The NY-ESO-1-specific CD8+ T cells are able to recognized and kill autologous leukemic cells and produces effectorcytokines (Nishikawa et al., 2012 PMID:22323448).

NY-ESO-1 is expressed in a substantial subset of triple negative breast cancer patients and leads to a high humoral immune response in a large proportion of these individuals (Ademuyiwa et al., 2012 PMID:22761704).

CTAG1B-specific T cell response has been observed in multiple myeloma patients. The response persists following autologous stem cell transplantation (Toor et al., 2012 PMID:22816680).

Gupta et al., 2013 (PMID:23390374) cloned the first human-derived antibody against NY-ESO-1 and proposed the systemic injection of monoclonal antibodies against tumor-associated antigens plus a treatment that promotes the local release of those antigens resulting in immune complex formation as a novel therapeutic modality for cancer.

The following NY-ESO-1 epitopes recognized by T cells have been identified after stimulation of lymphocytes in vitro (Cancer Immunity Peptide Database).